Rebiotix, based in Roseville, Minnesota, and Ferring Pharmaceuticals, with headquarters in Saint-Prex, Switzerland, announced positive preliminary results from the companies’ ongoing pivotal Phase III trial of RBX2660.

Arcadia Consumer Healthcare Inc., (formerly Kramer Laboratories Inc.) a recognized leader in the consumer healthcare industry, announced that the company completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.

The U.S. Food and Drug Administration approved Merck’s Dificid (fidaxomicin) for a new oral suspension as well as for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in children ages 6 months and older.

Bausch Health Companies Inc., together with wholly owned subsidiary Salix Pharmaceuticals Inc.’s licensor Alfasigma SpA, announced the filing of a lawsuit against Sandoz Inc. alleging patent infringement of 14 patents by the Novartis division’s submission of an Abbreviated New Drug Application for Xifaxan

(rifaximin) 550 mg tablets.

The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.

Ipsen today announced that the European Commission approved Xermelo (telotristat ethyl) 250 mg three times a day for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.